MS4A15 acts as an oncogene in ovarian cancer through reprogramming energy metabolism

Yuan Fang1, Huaiying Yu1, Honger Zhou1

  • 1Department of Gynecology, The First People's Hospital of Fuyang, Beihuan Road 429#, Fuyang District, Hangzhou, 311400, China.

Insights

Membrane-spanning 4-domains subfamily A 15 (MS4A15) promotes ovarian cancer (OC) growth by reprogramming cell metabolism. Inhibiting MS4A15 could be a new therapeutic strategy for OC patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Metabolism

Background:

  • Cell metabolism dysregulation is key in cancer development.
  • The role of Membrane-spanning 4-domains subfamily A 15 (MS4A15) in ovarian cancer (OC) is unknown.
  • MS4A15 is a transmembrane protein involved in biological events.

Purpose of the Study:

  • To investigate the role of MS4A15 in ovarian cancer (OC) progression.
  • To elucidate the underlying mechanisms of MS4A15 in OC.
  • To evaluate MS4A15 as a potential therapeutic target for OC.

Main Methods:

  • Analyzed MS4A15 expression in OC patient tissues and correlated with survival.
  • Performed in vitro studies (cell proliferation, cell cycle analysis) with MS4A15 knockdown and overexpression.
  • Utilized xenograft mouse models to assess tumor growth and KI-67 expression.
  • Investigated MS4A15's impact on lipid synthesis and oxidative phosphorylation (OXPHOS) under varying glucose conditions.

Main Results:

  • MS4A15 was significantly upregulated in OC tissues and associated with poorer survival.
  • MS4A15 knockdown inhibited OC cell proliferation and tumor growth in vivo.
  • MS4A15 overexpression accelerated OC cell proliferation and tumor growth.
  • MS4A15 reprogrammed energy metabolism, enhancing lipid synthesis and OXPHOS.

Conclusions:

  • MS4A15 plays a crucial role in promoting ovarian cancer (OC) growth.
  • MS4A15 facilitates OC progression by reprogramming cell metabolism.
  • MS4A15 represents a potential novel therapeutic target for ovarian cancer (OC) treatment.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.0K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
4.5K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.1K
Somatic to iPS Cell Reprogramming01:29

Somatic to iPS Cell Reprogramming

Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012...
2.3K
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.8K